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ABSTRACT
In total, 54 731 Gram-negative bacilli isolated worldwide between 2001 and 2004 from diverse sites of
infection were tested for susceptibility to polymyxin B by the broth reference microdilution method, with
interpretation of results according to CLSI (formerly NCCLS) guidelines. Polymyxin B showed excellent
potency and spectrum against 8705 Pseudomonas aeruginosa and 2621 Acinetobacter spp. isolates (MIC50,
£ 1 mg ⁄L and MIC90, 2 mg ⁄L for both pathogens). Polymyxin B resistance rates were slightly higher for
carbapenem-resistant P. aeruginosa (2.7%) and Acinetobacter spp. (2.8%), or multidrug-resistant (MDR) P.
aeruginosa (3.3%) and Acinetobacter spp. (3.2%), when compared with the entire group (1.3% for P.
aeruginosa and 2.1% for Acinetobacter spp.). Among P. aeruginosa, polymyxin B resistance rates varied
from 2.9% in the Asia-Paciﬁc region to only 1.1% in Europe, Latin America and North America, while
polymyxin B resistance rates ranged from 2.7% in Europe to 1.7% in North America and Latin America
among Acinetobacter spp. Polymyxin B also demonstrated excellent activity (MIC90, £ 1 mg ⁄L; > 98%
susceptible) against Citrobacter spp., Escherichia coli and Klebsiella spp., but activity was more variable
against Enterobacter spp. (MIC50, £ 1 mg ⁄L; 83.3% susceptible) and Stenotrophomonas maltophilia (MIC50,
£ 1 mg ⁄L; 72.4% susceptible), and was very limited (MIC50, > 8 mg ⁄L) against Burkholderia cepacia
(11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and
Proteus mirabilis (0.7% susceptible).
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INTRODUCTION
The polymyxins are amphipatic polypeptide
antimicrobial agents. Their basic structure con-
sists of a fatty-acid side-chain attached to a
polycationic peptide ring composed of eight to
ten amino-acids [1]. The polymyxins possess a
unique mechanism of action, targeting the bac-
terial cell-membrane. The polycationic peptide
ring of the polymyxins interacts with the
anionic lipopolysaccharide (LPS) molecules in
the outer-membrane of Gram-negative bacteria,
thereby displacing the calcium and magnesium
cations that stabilise the LPS molecules. This
process is independent of the entry of polymyx-
ins into the cell, and results in an increase in
cell-envelope permeability, leakage of cell con-
tents and, consequently, cell death [2,3]. More-
over, the fatty-acid side-chain of polymyxins
interacts with the LPS molecules to facilitate
further complexing between the polymyxins and
the cell-membrane [4]. In addition to their
antibacterial action, the polymyxins also possess
anti-endotoxin activity. The endotoxin of Gram-
negative bacteria is the lipid A portion of LPS
molecules, which is neutralised by the action of
polymyxin [5].
The polymyxins have activity against a wide
variety of Gram-negative bacilli, including
Enterobacteriaceae and non-fermentative isolates
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[6,7]. Polymyxins B and E (colistin) were intro-
duced into clinical practice during the 1950s for
the treatment of Gram-negative infections. How-
ever, the parenteral use of these compounds was
abandoned during the 1970s when better-toler-
ated anti-pseudomonal agents became available
[4,8]. The emergence of multidrug-resistant
(MDR) isolates of Pseudomonas aeruginosa and
Acinetobacter spp. has required the expanded
systemic use of these polymyxins [9]. Carbape-
nem resistance has been increasing among
P. aeruginosa and Acinetobacter spp. isolates [10–
12]. As the use of polymyxin increases, the
emergence of polymyxin resistance may become
a concern. The main objective of this study was to
assess the contemporary activity and spectrum of
polymyxin B, as a marker of polymyxin potency,
against a worldwide collection of Gram-negative
bacilli isolated through the SENTRY antimicrobial
surveillance programme (2001–2004).
MATERIALS AND METHODS
Study design
The SENTRY programme monitored the predominant patho-
gens and their antimicrobial resistance patterns, via a broad
network of sentinel hospitals, in four major geographical
regions: Asia-Paciﬁc, Europe, Latin America and North Amer-
ica (USA and Canada). Guided by common protocols, bacterial
isolates from diverse body sites were forwarded to the regional
monitors (JMI Laboratories, North Liberty, IA, USA, for
isolates from North America, Latin America and Europe; the
Women’s and Children’s Hospital, Adelaide, Australia, for
isolates from the Asia-Paciﬁc region) for conﬁrmation of
organism identiﬁcation and reference susceptibility testing.
Only a single isolate per patient was referred to the monitoring
centre. Common reagents and methodologies were used in
both central laboratories.
Participating medical centres
The number of participating centres varied according to the
geographical region, with 42 North American sites (ﬁve in
Canada and 37 in the USA), 30 in Europe, 12 in Latin America,
and 17 in the Asia-Paciﬁc region.
Bacterial isolates
In total, 54 731 aerobic Gram-negative bacterial isolates were
collected between January 2001 and December 2004. All
isolates were identiﬁed at the participating institution by the
routine methodology in use at each laboratory. Isolates with
imipenem or meropenem MICs ‡ 16 mg ⁄L were considered to
be resistant to carbapenems. Isolates exhibiting resistance to
piperacillin ⁄ tazobactam, ceftazidime, cefepime, imipenem,
meropenem, ciproﬂoxacin and amikacin were categorised as
MDR.
Susceptibility testing
Antimicrobial susceptibility testing was performed by broth
microdilution according to CLSI (formerly NCCLS) guidelines
and the results were interpreted following the latest suggested
breakpoints (polymyxin B susceptible breakpoint of £ 2 mg ⁄L)
[13,14]. Dry-form microdilution panels and broth for inocula-
tion were from Trek Diagnostics Inc. (Cleveland, OH, USA);
selected comparator agents were: cefepime, ceftazidime, pip-
eracillin ⁄ tazobactam, imipenem, meropenem, ciproﬂoxacin,
amikacin, gentamicin, trimethoprim ⁄ sulphamethoxazole
(Burkholderia cepacia and Stenotrophomonas maltophilia only),
ampicillin ⁄ sulbactam (Acinetobacter spp. only) and ticarcil-
lin ⁄ clavulanate (S. maltophilia only). Quality control strains
Escherichia coli ATCC 25922 and 35218, and P. aeruginosa ATCC
27853, were tested for quality assurance purposes, with all
results within published ranges [14].
RESULTS
The antimicrobial activity of polymyxin B against
13 808 non-fermentative isolates of Gram-negative
bacteria is summarised in Table 1 in comparison
with the other antimicrobial agents tested. Only
polymyxin B demonstrated reasonable potency
and spectrum against Acinetobacter spp. (MIC50 ⁄ 90,
£ 1 ⁄ 2 mg ⁄L; 97.9% susceptible) and P. aeruginosa
(MIC50 ⁄ 90, £ 1 ⁄ 2 mg ⁄L; 98.7% susceptible). Sus-
ceptibility rates for the other antimicrobial agents
tested ranged between 44.3% (ciproﬂoxacin) and
81.1% (imipenem) for Acinetobacter spp., and
between 70.5% (ciproﬂoxacin) and 88.3% (amika-
cin) forP. aeruginosa. Polymyxin B showed variable
activity against some other non-fermentative
Gram-negative bacilli, such as Pseudomonas spp.
other than P. aeruginosa (MIC50 ⁄ 90, £ 1 ⁄ 4 mg ⁄L;
88.3% susceptible) and S. maltophilia (MIC50 ⁄ 90,
1 ⁄ 8 mg ⁄L; 72.4% susceptible), and only very
limited activity against B. cepacia (MIC50,
> 8 mg ⁄L; 11.8% susceptible). Trimethoprim ⁄
sulphamethoxazole (MIC50, £ 0.5 mg ⁄L; 85.6%
susceptible) was the most potent agent against
B. cepacia, but meropenem (MIC50, 1 mg ⁄L; 94.1%)
exhibited the highest susceptibility rate, followed
by ceftazidime (MIC50, 2 mg ⁄L; 92.2%).
The activity of polymyxin B against 40 923
isolates of Enterobacteriaceae is summarised in
Table 2. Polymyxin B exhibited the highest activ-
ity (MIC90, £ 1 mg ⁄L) against Citrobacter spp.
(99.1% susceptible), E. coli (99.5% susceptible),
Klebsiella spp. (98.2% susceptible) and Shigella
spp. (99.0% susceptible). However, polymyxin B
showed variable activity against Enterobacter spp.
(83.3% susceptible) and Salmonella (76.0% sus-
ceptible), and only limited activity (MIC50,
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> 8 mg ⁄L) against Serratia spp., indole-positive
Proteus spp. and Proteus mirabilis.
The antimicrobial susceptibility of isolates of
P. aeruginosa and Acinetobacter spp. varied accord-
ing to their geographical origin (Table 3). In
general, isolates of Acinetobacter spp. tested were
resistant to many antimicrobial agents, independ-
ent of their region of isolation. The lowest sus-
ceptibility rates to carbapenems were observed
among isolates collected in Europe and the Asia-
Paciﬁc region (73.7% susceptible to imipenem),
while isolates from Latin America demonstrated
the lowest susceptibility rates to broad-spectrum
cephalosporins (32.4% susceptible to ceftazi-
dime), ﬂuoroquinolones (ciproﬂoxacin 34.8%),
and amikacin (40.4%).
Isolates of P. aeruginosa collected in Latin
America exhibited higher resistance rates than
those collected from other regions. P. aeruginosa
isolates from Latin America had the lowest
susceptibility rates to all antimicrobial agents
tested (Table 3) except for polymyxin B. Poly-
myxin B resistance rates were 2.9% in the Asia-
Paciﬁc region and 1.1% in Europe, Latin America
and North America. Among isolates of Acineto-
bacter spp., the frequency of polymyxin B resist-
ance varied from 2.7% in Europe to 1.9% in the
Asia-Paciﬁc region and 1.7% in Latin America
and North America.
The isolation frequency of polymyxin B-resist-
ant Acinetobacter spp. and P. aeruginosa did not
increase during the study period. Polymyxin
B-resistant Acinetobacter spp. were detected in 33
medical centres located in 18 countries. In Latin
America, ten of 11 polymyxin B-resistant isolates
of Acinetobacter spp. were identiﬁed in a single
Brazilian medical centre. In contrast, polymyxin
B-resistant Acinetobacter spp. from other geo-
graphical regions were distributed homogen-
eously among the participating medical centres.
Table 1. Antimicrobial activity of polymyxin B, compared
with other antimicrobial agents tested, against 13 808 non-
fermentative Gram-negative isolates (SENTRY antimicro-
bial surveillance programme 2001–2004)
Organism ⁄ antimicrobial
agent (number tested)
MIC (mg ⁄L)
% susceptible ⁄
resistanta50% 90% Range
Acinetobacter spp. (2621)
Polymyxin B £1 2 £1–>8 97.9 ⁄ 2.1
Ceftazidime 16 >16 £1–>16 44.6 ⁄ 48.3
Cefepime 16 >16 £0.12–>16 47.7 ⁄ 37.3
Ampicillin ⁄ sulbactam 8 >32 £0.25–>32 56.2 ⁄ 31.6
Imipenem 0.5 >8 £0.06–>8 81.1 ⁄ 15.8
Meropenem 1 >8 0.016–>8 77.7 ⁄ 17.0
Ciproﬂoxacin >2 >2 £0.016–>2 44.3 ⁄ 55.0
Amikacin 4 >32 £0.25–>32 60.2 ⁄ 35.8
Aeromonas spp. (368)
Polymyxin B £1 >8 £1–>8 71.7 ⁄ 28.3
Ceftazidime £2 £2 £2–>16 96.2 ⁄ 3.0
Cefepime £0.12 0.25 £0.12–>16 98.9 ⁄ 0.8
Piperacillin ⁄ tazobactam 4 >64 £0.5–>64 73.0 ⁄ 11.4
Imipenem 0.5 2 £0.06–>8 98.6 ⁄ 0.3
Meropenem 0.12 1 £0.06–8 99.7–>0.0
Ciproﬂoxacin £0.03 0.25 £0.03–>4 97.6 ⁄ 1.6
Amikacin 2 4 0.5–>32 98.1 ⁄ 0.5
Alcaligenes spp. (121)
Polymyxin B 2 >8 £1–>8 63.6 ⁄ 36.4
Ceftazidime 4 16 £2–>16 83.5 ⁄ 9.9
Cefepime 16 >16 £0.12–>16 18.3 ⁄ 48.3
Piperacillin ⁄ tazobactam 1 32 £0.5–>64 89.3 ⁄ 8.3
Imipenem 1 4 £0.5–>8 92.6 ⁄ 3.3
Meropenem 0.25 4 £0.06–>8 91.5 ⁄ 6.8
Ciproﬂoxacin 4 >4 0.06–>4 18.2 ⁄ 61.2
Amikacin >32 >32 0.5–>32 14.9 ⁄ 79.3
Burkholderia cepacia (153)
Polymyxin B >8 >8 0.5–>8 11.8 ⁄ 88.2
Ceftazidime 2 8 £1–>16 92.2 ⁄ 5.2
Cefepime 8 >16 £0.12–>16 73.2 ⁄ 13.1
Piperacillin ⁄ tazobactam 4 64 £0.5–>64 83.0 ⁄ 7.8
Imipenem 4 >8 £0.06–>8 58.2 ⁄ 10.5
Meropenem 2 4 £0.06–>16 94.1 ⁄ 4.6
Ciproﬂoxacin 1 >4 £0.016–>4 54.9 ⁄ 28.8
Amikacin >32 >32 £0.25–>32 15.7 ⁄ 70.6
Trimethoprim ⁄ sulphamethoxazole £0.5 >2 £0.5–>2 85.6 ⁄ 14.4
Pseudomonas aeruginosa (8705)
Polymyxin B £1 2 £1–>8 98.7 ⁄ 1.3
Ceftazidime 4 >16 £1–>16 76.6 ⁄ 18.7
Cefepime 4 >16 £0.12–>16 77.1 ⁄ 11.3
Piperacillin ⁄ tazobactam 8 >64 £0.12–>64 82.8 ⁄ 17.2
Imipenem 1 >8 £0.06–>8 79.3 ⁄ 12.5
Meropenem 0.5 >8 0.016–>8 81.8 ⁄ 12.0
Ciproﬂoxacin 0.25 >4 £0.016–>4 70.5 ⁄ 25.3
Amikacin 4 32 £0.25–>32 88.3 ⁄ 8.9
Pseudomonas spp. (non-aeruginosa; 282)b
Polymyxin B £1 4 £1–>8 88.3 ⁄ 11.7
Ceftazidime 2 >16 £1–>16 83.0 ⁄ 13.1
Cefepime 2 16 £0.12–>16 80.5 ⁄ 7.8
Piperacillin ⁄ tazobactam 8 >64 £0.5–>64 77.7 ⁄ 12.1
Imipenem 1 8 £0.06–>8 85.1 ⁄ 8.2
Meropenem 1 >8 0.03–>8 80.2 ⁄ 11.9
Ciproﬂoxacin 0.12 4 £0.016–>4 75.2 ⁄ 19.9
Amikacin 2 16 £0.25–>32 90.1 ⁄ 7.1
Stenotrophomonas maltophilia (1256)
Polymyxin B 1 8 £0.12–>8 72.4 ⁄ 27.6
Ceftazidime 8 >16 £1–>16 52.4 ⁄ 34.7
Ticarcillin ⁄ clavulanate 32 128 £16–>128 47.6 ⁄ 17.4
Levoﬂoxacin 1 4 £0.03–>4 86.9 ⁄ 5.8
Trimethoprim ⁄ sulphamethoxazole £0.5 1 £0.5–>2 97.0 ⁄ 3.0
Other non-enteric Gram-negative bacilli (302)c
Polymyxin B 4 >4 <1–>8 44.4 ⁄ 55.6
Ceftazidime £2 >16 £2–>16 78.1 ⁄ 16.2
Cefepime 0.5 16 £0.12–>16 83.4 ⁄ 7.8
Piperacillin ⁄ tazobactam £0.5 >64 £0.5–>64 90.1 ⁄ 5.0
Imipenem £0.5 >8 £0.5–>8 84.1 ⁄ 12.9
Meropenem £0.06 >8 £0.06–>8 80.7 ⁄ 16.3
Ciproﬂoxacin 0.12 >4 £0.03–>4 87.4 ⁄ 7.0
Amikacin 8 >32 £0.25–>32 70.2 ⁄ 18.9
Table 1. Continued
aCriteria as published by the CLSI [14].
bIncludes P. alcaligenes (n = 3), P. ﬂuorescens (n = 52), P. ﬂuorescens ⁄ putida (n = 18), P.
luteola (n = 7), P. mendocina (n = 6), P. oryzihabitans (n = 24), P. putida (n = 39),
Pseudomonas spp. (n = 117) and P. stutzeri (n = 16).
cAchromobacter species (n = 14), Actinobacillus actinomycetemcomitans (n = 2), Agro-
bacterium spp. (n = 17), Bordetella bronchiseptica (n = 1), Brevundimonas vesicularis
(n = 3), Burkholderia spp. (n = 3), Capnocytophaga spp. (n = 2), CDC Group IVc2
(n = 3), Chromobacterium violaceum (n = 2), Chryseobacterium spp. (n = 48), Coma-
monas spp. (n = 2), Delftia acidovorans (n = 10), Eikenella corrodens (n = 2), Kingella
spp. (n = 3), Myroides ordoratum (n = 2), Ochrobactrum anthropi (n = 12), Pasteurella
spp. (n = 59), Plesiomonas shigelloides (n = 13), Ralstonia spp. (n = 14), Roseomonas
spp. (n = 4), Shewanella spp. (n = 8), Sphingobacterium spp. (n = 3), Sphingomonas
paucimobilis (n = 19), Vibrio spp. (n = 55), Yokenella regensburgei (n = 1).
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Polymyxin B-resistant P. aeruginosa isolates were
detected in 51 medical centres located in 20
countries, but no single centre had a high preval-
ence of polymyxin B-resistant P. aeruginosa iso-
Table 2. Antimicrobial activity of polymyxin B, compared
with other antimicrobial agents tested, against 40 923
isolates of Enterobacteriaceae (SENTRY antimicrobial sur-
veillance programme, 2001–2004)
Organism ⁄ antimicrobial
agent (no. tested)
MIC (mg ⁄L)
% susceptible ⁄
resistanta50% 90% Range
Citrobacter spp.b (895)
Polymyxin B £1 £1 £1–>8 99.1 ⁄ 0.9
Ceftriaxone £0.25 32 £0.25–>32 83.9 ⁄ 6.6
Cefepime £0.12 1 £0.12–>16 98.1 ⁄ 1.6
Piperacillin ⁄ tazobactam 2 64 £0.5–>64 86.0 ⁄ 5.6
Imipenem £0.5 1 £0.5–>8 99.9 ⁄ 0.1
Ciproﬂoxacin £0.03 1 £0.03–>4 90.6 ⁄ 7.7
Gentamicin £2 £2 £2–>8 91.5 ⁄ 7.4
Enterobacter spp.c (4693)
Polymyxin B £1 >8 £1–>8 83.3 ⁄ 16.7
Ceftriaxone £0.25 >32 £0.25–>32 76.1 ⁄ 13.8
Cefepime £0.12 4 £0.12–>16 95.5 ⁄ 2.9
Piperacillin ⁄ tazobactam 2 >64 £0.12–>64 77.4 ⁄ 10.2
Imipenem £0.5 1 £0.5–>8 99.4 ⁄ 0.3
Ciproﬂoxacin £0.03 >2 £0.03–>2 87.2 ⁄ 10.8
Gentamicin £2 >8 £2–>8 88.3 ⁄ 10.3
Escherichia coli (18 325)
Polymyxin B £1 £1 £1–>8 99.5 ⁄ 0.5
Ceftriaxone £0.25 £0.25 £0.25–>32 96.2 ⁄ 3.0
Cefepime £0.12 £0.12 £0.12–>16 97.6 ⁄ 1.9
Piperacillin ⁄ tazobactam 2 4 £0.12–>64 96.2 ⁄ 1.8
Imipenem £0.5 £0.5 £0.5–>8 >99.9 ⁄ < 0.1
Ciproﬂoxacin £0.03 >4 £0.03–>4 85.5 ⁄ 14.4
Gentamicin £2 £2 £2–>8 92.1 ⁄ 7.1
Klebsiella spp.d (8188)
Polymyxin B £1 £1 £1–>8 98.2 ⁄ 1.8
Ceftriaxone £0.25 32 £0.25–>32 85.5 ⁄ 9.7
Cefepime £0.12 4 £0.12–>16 92.4 ⁄ 5.9
Piperacillin ⁄ tazobactam 2 64 £0.12–>64 87.4 ⁄ 9.6
Imipenem £0.5 £0.5 £0.5–>8 99.7 ⁄ 0.2
Ciproﬂoxacin £0.03 2 £0.03–>4 89.5 ⁄ 8.9
Gentamicin £2 >8 £2–>8 85.9 ⁄ 12.8
Indole-positive Proteus spp.e (895)
Polymyxin B >8 >8 £1–>8 1.3 ⁄ 98.7
Ceftriaxone £0.25 2 £0.25–>32 95.6 ⁄ 2.6
Cefepime £0.12 0.25 £0.12–>16 97.7 ⁄ 1.5
Piperacillin ⁄ tazobactam £0.5 4 £0.5–>64 98.3 ⁄ 0.6
Imipenem 2 2 £0.12–>8 99.3 ⁄ 0.1
Ciproﬂoxacin £0.03 >4 £0.03–>4 81.1 ⁄ 16.6
Gentamicin £2 >8 £2–>8 85.8 ⁄ 11.6
Proteus mirabilis (1931)
Polymyxin B >8 >8 £1–>8 0.7 ⁄ 99.3
Ceftriaxone £0.25 £0.25 £0.25–>32 94.7 ⁄ 3.3
Cefepime £0.12 0.25 £0.12–>16 96.2 ⁄ 2.9
Piperacillin ⁄ tazobactam £0.5 1 £0.5–>64 99.0 ⁄ 0.2
Imipenem 1 2 £0.5–8 99.8 ⁄ 0.0
Ciproﬂoxacin £0.03 4 £0.03–>4 80.8 ⁄ 14.3
Gentamicin £2 >8 £2–>8 87.8 ⁄ 10.4
Salmonella spp. (2909)
Polymyxin B £1 4 £1–>8 76.0 ⁄ 24.0
Ceftriaxone £0.25 £0.25 £0.25–>32 98.9 ⁄ 0.7
Cefepime £0.12 £0.12 £0.12–>16 99.5 ⁄ 0.1
Piperacillin ⁄ tazobactam 2 4 £0.5–>64 97.8 ⁄ 1.3
Imipenem £0.5 £0.5 £0.5–2 100.0 ⁄ 0.0
Ciproﬂoxacin £0.03 0.12 £0.03–>4 99.3 ⁄ 0.7
Gentamicin £2 £2 £2–>8 97.0 ⁄ 2.2
Shigella spp. (828)
Polymyxin B £1 £1 £1–>8 99.0 ⁄ 1.0
Ceftriaxone £0.25 £0.25 £0.25–>32 99.8 ⁄ 0.2
Cefepime £0.12 0.25 £0.12–>16 99.9 ⁄ 0.1
Piperacillin ⁄ tazobactam 2 4 £0.5–>64 99.9 ⁄ 0.1
Imipenem £0.5 £0.5 £0.5–1 100.0 ⁄ 0.0
Ciproﬂoxacin £0.03 £0.03 £0.03–1 100.0 ⁄ 0.0
Gentamicin £2 £2 £2–>8 99.6 ⁄ 0.4
Serratia spp.f (1919)
Polymyxin B >8 >8 0.25–>8 5.4 ⁄ 94.6
Ceftriaxone £0.25 8 £0.25–>32 90.0 ⁄ 5.2
Cefepime £0.12 1 £0.12–>16 95.5 ⁄ 3.4
Piperacillin ⁄ tazobactam 2 32 £0.5–>64 88.5 ⁄ 3.0
Imipenem £0.5 1 £0.5–>8 99.3 ⁄ 0.5
Ciproﬂoxacin 0.06 1 £0.03–>4 90.5 ⁄ 6.1
Gentamicin £2 8 £2–>8 88.3 ⁄ 9.7
Table 2. Continued
Organism ⁄ antimicrobial
agent (no. tested)
MIC (mg ⁄L)
% susceptible ⁄
resistanta50% 90% Range
Other enteric Gram-negative bacilli (340)g
Polymyxin B £1 8 £1–>8 75.9 ⁄ 24.1
Ceftriaxone £0.25 8 £0.25–>32 91.5 ⁄ 1.8
Cefepime £0.12 0.5 £0.12–>16 99.1 ⁄ 0.3
Piperacillin ⁄ tazobactam 2 16 £0.5–>64 91.5 ⁄ 3.2
Imipenem £0.5 £0.5 £0.5–>8 99.1 ⁄ 0.6
Meropenem £0.06 £0.06 £0.06–>8 99.7 ⁄ 0.3
Ciproﬂoxacin £0.03 0.06 £0.03–>4 98.2 ⁄ 1.8
Gentamicin £2 £2 £2–>8 95.9 ⁄ 2.7
aCriteria as published by the CLSI [14].
bIncludes: Citrobacter amalonaticus (n = 14), Citrobacter braakii (n = 38), Citrobacter
diversus (n = 1), Citrobacter fameri (n = 5), Citrobacter freundii (n = 503), Citrobacter
koseri (n = 282), Citrobacter spp. (n = 50) and Citrobacter youngae (n = 2).
cIncludes: Enterobacter spp. (n = 300), Enterobacter amnigenus (n = 17), Enterobacter
cloacae (n = 3305), Enterobacter asburiae (n = 24), Enterobacter intermedius (n = 6),
Enterobacter gergoviae (n = 16), Enterobacter cancerogenus (n = 9), Enterobacter hor-
maechei (n = 6), Enterobacter taylorae (n = 3), Enterobacter sakazakii (n = 23) and
Enterobacter aerogenes (n = 984).
dIncludes: Klebsiella oxytoca (n = 1363), Klebsiella ozaenae (n = 13), Klebsiella spp.
(n = 157), Klebsiella ornithinolytica (n = 7), Klebsiella pneumoniae (n = 6642), Klebsiella
terrigena (n = 3) and Klebsiella planticola (n = 3).
eIncludes: Morganella morganii (n = 507), Proteus spp. (n = 64), Proteus vulgaris
(n = 179), Providencia alcalifaciens (n = 1), Providencia rettgeri (n = 41), Providencia
spp. (n = 18) and Providencia stuartii (n = 85).
fIncludes: Serratia rubidaea (n = 10), Serratia marcescens (n = 1771), Serratia plymuthica
(n = 14), Serratia liquefaciens (n = 40), Serratia odorifera (n = 4), Serratia fonticola
(n = 10) and Serratia spp. (n = 70).
gCedecea spp. (n = 2), Edwardsiella tarda (n = 1), Escherichia spp. (n = 48), Ewingella
americana (n = 3), Hafnia spp. (n = 59), Kluyvera spp. (n = 15), Leclercia adecarboxylata
(n = 6), Pantoea agglomerans (n = 127), Pantoea spp. (n = 4), Proteus penneri (n = 17),
Tatumella spp. (n = 1), Yersinia enterocolitica (n = 55) and Yersinia pseudotuberculosis
(n = 2).
Table 3. Antimicrobial activity of polymyxin B, compared
with other antimicrobial agents, against Pseudomonas aeru-
ginosa and Acinetobacter spp., grouped according to the
region of isolation (SENTRY antimicrobial surveillance
programme, 2001–2004)
Antimicrobial agent
% susceptible (no. of isolates)
APACa Europe Latin America North America
Acinetobacter spp. (411) (851) (664) (695)
Polymyxin B 98.1 97.3 98.3 98.3
Ceftazidime 58.4 39.7 32.4 54.2
Cefepime 58.4 43.9 36.4 56.8
Ampicillin ⁄ sulbactam 59.2 48.4 51.8 70.5
Imipenem 73.7 73.7 86.4 89.4
Meropenem 73.0 70.4 83.6 83.7
Ciproﬂoxacin 55.0 38.7 34.8 54.0
Amikacin 64.0 55.0 40.4 83.2
Pseudomonas aeruginosa (898) (3145) (1626) (3036)
Polymyxin B 97.1 98.9 98.9 98.9
Ceftazidime 81.6 74.9 60.9 85.4
Cefepime 82.3 75.4 62.0 85.4
Piperacillin ⁄ tazobactam 86.1 81.2 72.0 89.2
Imipenem 82.2 78.1 66.1 86.9
Meropenem 85.7 80.6 68.0 89.4
Ciproﬂoxacin 81.2 70.1 57.3 74.9
Amikacin 92.7 88.0 70.8 96.6
aAsia-Paciﬁc (APAC) region. Includes Australia, China, Hong Kong, Japan, Korea,
Philippines, Singapore, Taiwan and South Africa.
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lates. Most polymyxin B-resistant P. aeruginosa
isolates had a polymyxin B MIC of 4 mg ⁄L. In
contrast, almost two-thirds of the polymyxin
B-resistant Acinetobacter spp. isolates had polym-
yxin B MICs ‡ 8 mg ⁄L.
In total, 495Acinetobacter spp. and 1398 P. aerugi-
nosa were resistant to carbapenems (imipenem or
meropenem MIC ‡ 16 mg ⁄L; Table 4), while 231
Acinetobacter spp. and 209 P. aeruginosa were
considered to be MDR isolates (data not shown).
Polymyxin B was the most potent agent (MIC50,
£ 1 mg ⁄L) against carbapenem-resistant isolates of
Acinetobacter spp. and P. aeruginosa, and exhibited
the highest susceptibility rates (97.2% and 97.6%,
respectively), followed by amikacin (22.8% and
58.3%, respectively). Interestingly, 45.4% and
33.4%, respectively, of the carbapenem-resistant
P. aeruginosa isolates were still susceptible to pip-
eracillin ⁄ tazobactam and ceftazidime (Table 4).
Polymyxin B resistance rates were slightly higher
among carbapenem-resistant P. aeruginosa (2.7%)
and Acinetobacter spp. (2.8%), or MDR P. aerugi-
nosa (3.3%) and Acinetobacter spp. (3.2%), when
comparedwith the entire group of isolates (1.3 and
2.1%, respectively).
DISCUSSION
Polymyxin B remains very active against contem-
porary clinical isolates of P. aeruginosa and Acine-
tobacter spp., including isolates resistant to
carbapenems, and was also very active against
extended-spectrum b-lactamase-producing iso-
lates of E. coli and Klebsiella spp. The results of
this study are in accordance with those published
previously [7,15]. Currently, parenteral use of
polymyxin B has been directed mainly to the
treatment of infections caused by MDR P. aerugi-
nosa and Acinetobacter spp. [9,16]. However, the
emergence of carbapenemase-producing Klebsiella
pneumoniae has led to the clinical utilisation of
polymyxins for treatment of such infections
[17,18]. Nearly 75.0% of the S. maltophilia isolates
evaluated in the present study were inhibited by
polymyxin B concentrations £ 2 mg ⁄L [14]. It is
important to establish the clinical relevance of this
ﬁnding, i.e., whether the polymyxins would be
effective clinically in preventing and ⁄ or treating
S. maltophilia infections, as many patients receiv-
ing polymyxins for treatment of nosocomial-
acquired pneumonia are at risk for S. maltophilia
superinfections.
Studies of polymyxin-resistant P. aeruginosa
isolates have suggested two distinct mechanisms
by which this organism can become resistant to
polymyxin B. The ﬁrst results from stepwise
adaptation to the presence of polymyxin in the
growth medium. Resistance acquired in this
manner is unstable, so that adapted isolates revert
to polymyxin susceptibility following growth in
polymyxin-free medium. This adaptive resistance
may be caused by loss of outer-membrane pro-
teins or by a reduction in the binding of poly-
myxin to the cell-envelope following changes in
lipid and LPS composition [19]. The second
mechanism involves genetic mutation. Unlike
adaptive resistance, mutational polymyxin resist-
ance is inheritable and is characterised by alter-
ations in the outer-membrane which are distinct
from those found in polymyxin-adapted strains,
such as an increased level of protein H1 and a
concomitant decrease in the Mg+2 content of the
cell envelope. This form of mechanism does not
involve porin proteins, and such isolates are
resistant to EDTA and gentamicin [19–22].
Polymyxin resistance has been documented
rarely, but the emergence of polymyxin-resistant
P. aeruginosa and Acinetobacter spp. would pose a
serious therapeutic problem, since no new anti-
microbial agents are available currently for treat-
ment of infections caused by MDR Gram-negative
bacilli. No increase in the isolation frequency of
polymyxin-resistant Acinetobacter spp. or P. aeru-
ginosa was observed in the 2001–2004 period
monitored for the SENTRY programme, despite
Table 4. Antimicrobial activity of polymyxin B compared
with other antimicrobial agents against carbapenem-resist-
ant isolates of Acinetobacter spp. and P. aeruginosa (SENTRY
antimicrobial surveillance programme 2001–2004)
Species (no.) ⁄
antimicrobial agent
mg ⁄La
MIC50 MIC90 % susceptible
b % resistantb
Acinetobacter spp. (495)c
Polymyxin B £1 2 97.2 2.8
Ceftazidime >16 >16 5.5 91.7
Cefepime >16 >16 5.3 71.9
Ampicillin ⁄ Sulbactam 32 >32 8.4 66.6
Ciproﬂoxacin >2 >2 6.3 92.9
Amikacin >32 >32 22.8 77.2
P. aeruginosa (1398)c
Polymyxin B £1 2 97.6 2.4
Ceftazidime 16 >16 33.4 59.4
Cefepime >16 >16 29.2 44.5
Piperacillin ⁄Tazobactam >64 >64 45.4 54.6
Ciproﬂoxacin >2 >2 27.8 77.5
Amikacin 16 >32 58.3 41.7
aMIC determined by broth microdilution according to CLSI ⁄NCCLS recommenda-
tions [13].
bPercentage of susceptibility and resistance calculated according to CLSI [14].
cIsolates with imipenem and ⁄ or meropenem MIC ‡16 mg ⁄L.
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the recent increased use of polymyxins (poly-
myxin B and colistin) at some of the sites monit-
ored. In contrast, Landman et al. [23] reported the
emergence of polymyxin-resistant P. aeruginosa
isolates in many associated hospitals located in
Brooklyn, New York, USA. The same authors
speculated that the emergence of this resistance
phenotype could be related to increased poly-
myxin usage. In a previous SENTRY report (iso-
lates collected in 1998), polymyxin B resistancewas
not observed among isolates of P. aeruginosa, and
only three isolates of Acinetobacter spp. were
reported to be resistant to this compound [7].
These three isolates were collected in Sao Paulo
(one) and New York (two). However, it is not
possible to state that polymyxin B-resistant
P. aeruginosa isolates have emerged after 1998,
since only a small number of isolates were evalu-
ated for polymyxin susceptibility before that date.
Most (83.0%) of the polymyxin B-resistant
P. aeruginosa isolates with a polymyxin B MIC of
4 mg ⁄L (low level of resistance) have been found
to have over-expression of OprH [20]. However,
isolates with polymyxin B MICs of 2 mg ⁄L could
have been categorised erroneously as resistant,
since an acceptable ±one-log2 variation in the MIC
can occur when testing this compound. In addi-
tion, variations in the cation concentration of the
standard medium (Mueller Hinton broth) may
cause an increase in the MIC and, consequently,
lead to false-resistance results [7]. Thus, it seems
prudent to retest isolates exhibiting polymyxin
MICs of 4 mg ⁄L by an alternative quantitative
method for resistance conﬁrmation. However, it is
important to emphasise that polymyxin suscepti-
bility testing should be performed with caution,
since variation in the divalent cationic concentra-
tion may lead to changes in MIC. In addition, agar
dilution and Etest may indicate higher MICs when
compared with broth microdilution [15,23,24].
On the other hand, most polymyxin-resistant
isolates of Acinetobacter spp. had MICs much
higher than those for P. aeruginosa isolates. It is
very important to establish the correlation
between these in-vitro ﬁndings and the clinical
response. However, this relationship will not be
assessed easily, since critically-ill patients infected
with MDR isolates are usually receiving poly-
myxins as well as other agents in a signiﬁcant
proportion of cases.
Although a single Brazilian medical centre con-
tributedmost of the polymyxin-resistant isolates of
Acinetobacter spp. collected in Latin America, the
suspicion of an outbreak was discounted after
evaluating epidemiological data. The genetic relat-
edness of polymyxin-resistant Acinetobacter spp.
from the same Brazilian medical centre has been
studied previously [25], and although three of ﬁve
isolates belonged to distinct genotypes, two
polymyxin-resistant isolates belonged to a unique
genotype, indicating possible intra-hospital dis-
semination. Landmann et al. [23] evaluated the
genetic relatedness of polymyxin-resistant P. aeru-
ginosa isolates by automated ribotyping, and repor-
ted that most of the isolates belonged to distinct
ribotypes and, thus, were not related genetically.
Since no antimicrobial agent effective against
MDR Acinetobacter spp. and P. aeruginosa is
currently under development, resistance surveil-
lance plays a crucial role in detecting the emer-
gence of polymyxin-refractory strains among
MDR Gram-negative bacilli. Clinical microbio-
logy laboratories must be able to detect this
resistance phenotype, and recent guidelines have
been published by the CLSI [14]. In this manner,
clinical correlation can be established and infec-
tion control measures can be initiated to minimise
the intra- and inter-hospital spread of polymyxin-
resistant clones.
ACKNOWLEDGEMENTS
We thank P. Strabala for excellent computer support. We also
would like to thank all participating medical centres in the
SENTRY antimicrobial surveillance programme, as well as
the technicians who have worked in the programme. This
study was presented, in part, at the 43rd Annual Meeting of
the Infectious Diseases Society of America (San Francisco,
2005).
REFERENCES
1. Katz E, Demain AL. The peptide antibiotics of Bacillus:
chemistry, biogenesis, and possible functions. Bacteriol Rev
1997; 41: 449–474.
2. Newton BA. The properties and mode of action of poly-
myxins. Bacteriol Rev 1956; 20: 14–17.
3. Schindler M, Osborn MJ. Interaction of divalent cations
and polymyxin B with lipopolysaccharide. Biochemistry
1979; 18: 4425–4430.
4. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins:
pharmacology, pharmacokinetics, pharmacodynamics,
and clinical applications. Infect Dis Clin North Am 2003; 17:
545–562.
5. Drabick JJ, Bhattacharjee AK, Hoover DL et al. Covalent
polymyxin B conjugate with human immunoglobulin G as
an antiendotoxin reagent. Antimicrob Agents Chemother
1998; 42: 583–588.
320 Clinical Microbiology and Infection, Volume 12 Number 4, April 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 315–321
6. Catchpole CR, Andrews JM, Brenwald N, Wise R. A
reassessment of the in-vitro activity of colistin sulpho-
methate sodium. J Antimicrob Chemother 1997; 39: 255–260.
7. Gales AC, Reis AO, Jones RN. Contemporary assessment
of antimicrobial susceptibility testing methods for
polymyxin B and colistin: review of available interpretat-
ive criteria and quality control guidelines. J Clin Microbiol
2001; 39: 183–190.
8. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and
colistin: old antibiotics for emerging multiresistant gram-
negative bacteria. Ann Pharmacother 1999; 33: 960–967.
9. Levin AS, Barone AA, Penco J et al. Intravenous colistin as
therapy for nosocomial infections caused by multidrug-
resistant Pseudomonas aeruginosa and Acinetobacter bau-
mannii. Clin Infect Dis 1999; 128: 1008–1011.
10. Andrade SS, Jones RN, Gales AC, Sader HS. Increasing
prevalence of antimicrobial resistance among Pseudomonas
aeruginosa isolates in Latin American medical centres: 5
year report of the SENTRY Antimicrobial Surveillance
Program (1997–2001). J Antimicrob Chemother 2003; 52: 140–
141.
11. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R.
Characterization of Pseudomonas aeruginosa isolates:
occurrence rates, antimicrobial susceptibility patterns, and
molecular typing in the global SENTRY Antimicrobial
Surveillance Program, 1997–99. Clin Infect Dis 2001; 32
(suppl 2): S146–S155.
12. Gales AC, Jones RN, Forward KR, Linares J, Sader HS,
Verhoef J. Emerging importance of multidrug-resistant
Acinetobacter species and Stenotrophomonas maltophilia as
pathogens in seriously ill patients: geographic patterns,
epidemiological features, and trends in the SENTRY
Antimicrobial Surveillance Program (1997–99). Clin Infect
Dis 2001; 32 (suppl 2): S104–S113.
13. National Committee for Clinical Laboratory Standards.
Methods for dilution antimicrobial susceptibility test for bacteria
that grow aerobically, 5th edn. Approved standard M7–A6.
Wayne, PA: NCCLS, 2003.
14. Clinical Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing. 16th
Informational Supplement M100–S16. Wayne, PA: CLSI,
2006.
15. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heese-
mann J. Pitfalls of polymyxin antimicrobial susceptibility
testing of Pseudomonas aeruginosa isolated from cystic
ﬁbrosis patients. J Antimicrob Chemother 2004; 54: 1057–
1061.
16. Falagas ME, Kasiakou SK. Colistin: the revival of
polymyxins for the management of multidrug-resistant
Gram-negative bacterial infections. Clin Infect Dis 2005; 40:
1333–1341.
17. Bradford PA, Bratu S, Urban C et al. Emergence of carb-
apenem-resistant Klebsiella species possessing the class A
carbapenem-hydrolyzing KPC-2 and inhibitor-resistant
TEM-30 beta-lactamases in New York City. Clin Infect Dis
2004; 39: 55–60.
18. Parchuri S, Mohan S, Cunha BA. Extended spectrum beta-
lactamase-producing Klebsiella pneumoniae chronic ambu-
latory peritoneal dialysis peritonitis treated successfully
with polymyxin B. Heart Lung 2005; 34: 360–363.
19. Moore RA, Chan L, Hancock RE. Evidence for two dis-
tinct mechanisms of resistance to polymyxin B in Pseu-
domonas aeruginosa. Antimicrob Agents Chemother 1984; 26:
539–545.
20. Nicas TI, Hancock REW. Outer membrane protein H1 of
Pseudomonas aeruginosa: involvement in adaptive and
mutational resistance to ethylenediaminetetraacetate,
polymyxin B, and gentamicin. J Bacteriol 1980; 143: 872–
878.
21. Gunn JS, Lim KB, Krueger J et al. PmrA-PmrB-regulated
genes necessary for 4-aminoarabinose lipid A modiﬁcation
and polymyxin resistance. Mol Microbiol 1998; 27: 1171–
1182.
22. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K.
Evaluation of colistin as an agent against multi-resistant
Gram-negative bacteria. Int J Antimicrob Agents; 2005; 5:
11–25.
23. Landman D, Bratu S, Alam M, Quale J. Citywide emer-
gence of Pseudomonas aeruginosa strains with reduced
susceptibility to polymyxin B. J Antimicrob Chemother 2005;
55: 954–957.
24. Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME et al.
Reliability of the E-test method for detection of colistin
resistance in clinical isolates of Acinetobacter baumannii.
J Clin Microbiol 2005; 43: 903–905.
25. Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC.
Polymyxin-resistant Acinetobacter spp. isolates: what is
next? Emerg Infect Dis 2003; 9: 1025–1027.
Gales et al. Polymyxin B activity – SENTRY programme 321
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 315–321
